产品编号 :
Cas No. :
CAS No. |
866206-55-5 |
|---|---|
中文名称 |
PRX-08066马来酸盐 |
英文名称 |
PRX-08066 Maleic acid |
别名 |
CCG-269838 | EX-A1246 | 5-[[4-[(6-Chlorothieno[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]-2-fluorobenzonitrile maleate | HMS3886N21 | S8010 | CS-0019705 | HY-15472A | (Z)-but-2-enedioic acid;5-[[4-[(6-chlorothieno[2,3-d]pyrimidin-4-yl)amino]piperid |
标准英文名 |
5-((4-((6-chlorothieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-2-fluorobenzonitrile fumarate |
分子式 |
C23H21ClFN5O4S |
分子量 |
517.97 |
精确分子量 |
517.10 |
SMILES |
N#CC1=CC(CN2CCC(NC3=NC=NC4=C3C=C(Cl)S4)CC2)=CC=C1F.O=C(O)/C=C/C(=O)O |
标准SMILES |
N#CC1=CC(CN2CCC(CC2)NC2=NC=NC3SC(Cl)=CC=32)=CC=C1F.OC(=O)/C=C/C(O)=O |
用途 |
PRX-08066 maleic acid is a selective 5-HT2B receptor antagonist (IC50 = 3.4 nM) used for the prevention and treatment of pulmonary arterial hypertension (PAH); it is currently in Phase 2 clinical trials. It inhibits pathological 5-HT-induced vascular remodeling associated with PAH by suppressing 5-HT-induced mitogen-activated protein kinase (MAPK) activation (IC50 = 12 nM), reducing thymidine incorporation (IC50 = 3 nM), and inhibiting cell proliferation (IC50 = 0.46 nM) and 5-HT secretion (IC50 = 6.9 nM) in 5-HT2B receptor-expressing SI-NET KRJ-I cells. It also suppresses isoproterenol-stimulated 5-HT release in NCI-H720 cells (IC50 = 1.25 nM). In vivo, PRX-08066 significantly attenuates monocrotaline (MCT)- or hypoxia-induced increases in right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary arterial pressure in rodent models, without affecting systemic mean arterial pressure. It also preserves cardiac function and reduces RV/(LV+S) ratios and RV/body weight ratios. Additionally, PRX-08066 downregulates pro-fibrotic and pro-proliferative factors (TGFβ1, CTGF, FGF2, TPH1), reduces Ki67 expression, and induces apoptosis via caspase-3 activation in tumor and cardiac tissues. |
InChIKey |
RPYIKXHIQXRXEM-WLHGVMLRSA-N |
|
|
评论 |
|---|